ChemioCare

ChemioCare is a clinical-stage biotechnology company focused on improving oncology supportive care through proprietary transdermal drug delivery technology. The company develops transdermal patches for high-potency generic medications to treat chemotherapy-induced nausea and vomiting (CINV). Its lead programs, including CMV-101 (granisetron) and CMV-103 (palonosetron), aim to provide sustained, controlled release of 5-HT3 receptor antagonists, offering a more convenient and effective alternative to oral or intravenous administration. By leveraging its permeation enhancement platform, ChemioCare seeks to reduce the side effects and pill burden for cancer patients undergoing treatment. The company utilizes the 505(b)(2) regulatory pathway to bring these improved formulations to market efficiently.